The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Abstract
Drugs targeting the cell cycle–regulatory cyclin-dependent kinase (CDK) 4 and 6 have been approved for the treatment of hormone receptor–positive breast cancer, and inhibitors targeting other cell-cycle CDKs are currently in clinical trials. Another class of CDKs, the transcription-associated CDKs, including CDK7, CDK8, CDK9, CDK12 and CDK13, are critical regulators of gene expression. Recent evidence suggests several novel functions of these CDKs, including regulation of epigenetic modifications, intronic polyadenylation, DNA-damage responses, and genomic stability. Here, we summarize our current understanding of the transcriptional CDKs, their utility as biomarkers, and their potential as therapeutic targets. Significance: CDK inhibitors targeting CDK4 and CDK6 have been approved in hormone receptor–positive breast cancer, and inhibitors targeting other cell-cycle CDKs are currently in clinical trials. Several studies now point to potential therapeutic opportunities by inhibiting the transcription-associated CDKs as well as therapeutic vulnerabilities with PARP inhibitors and immunotherapy in tumors deficient in these CDKs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationThe Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Self-citationLandscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
The Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M.-L., Varela, I., Pleasance, E. D., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 845
Alternative cleavage and polyadenylation: extent, regulation and function
Elkon, R., Ugalde, A. P., & Agami, R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3482 · Cited by 804
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
Self-citationCDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Self-citationDinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552 · cited 1×
“These compounds consist of a CDK-binding ligand (SNS-032) linked to a thalidomide derivative that binds to the E3 ubiquitin ligase Cereblon to promote degradation (137).”
BackgroundDynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation
Edmunds, J. W., Mahadevan, L. C., & Clayton, A. L. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601967 · Cited by 547 · cited 1×
“CDK7 stimulates the methyltransferase activity of SETD1A/B to regulate H3K4me3 downstream of the transcriptional start site, and may indirectly regulate H3K36me3 positioning through its effects on CDK9 and SETD2 (74, 75).”
BackgroundBlazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522 · cited 3×
“Interestingly, CDK12 depletion does not affect transcription globally, but instead alters a select subset of genes involved in the DNA damage response (DDR) and DNA replication (61, 64).”
BackgroundIdentification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms
Nguyen, V. Q., Co, C., & Li, J. J. (2001) · Nature · doi:10.1038/35082600 · Cited by 462
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Born to run: control of transcription elongation by RNA polymerase II
Chen, F. X., Smith, E. R., & Shilatifard, A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0010-5 · Cited by 447 · cited 2×
“Following initiation, RNA Pol II enters transcriptional pausing, during which NELF and DSIF are loaded onto RNA Pol II (48).”
BackgroundDual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Self-citationTargeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 432
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Self-citationMediator kinase inhibition further activates super-enhancer-associated genes in AML
Pelish, H. E., Liau, B. B., Nitulescu, I. I., Tangpeerachaikul, A., Poss, Z. C., Da Silva, D. H., Caruso, B. T., Arefolov, A., Fadeyi, O., Christie, A. L., et al. (2015) · Nature · doi:10.1038/nature14904 · Cited by 403
Structural basis of transcription initiation by RNA polymerase II
Sainsbury, S., Bernecky, C., & Cramer, P. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3952 · Cited by 401
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010) · Genes & Development · doi:10.1101/gad.1968210 · Cited by 400
TFIIH is negatively regulated by cdk8-containing mediator complexes
Akoulitchev, S., Chuikov, S., & Reinberg, D. (2000) · Nature · doi:10.1038/35024111 · Cited by 393
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Larochelle, S., Amat, R., Glover-Cutter, K., Sansó, M., Zhang, C., Allen, J. J., Shokat, K. M., Bentley, D. L., & Fisher, R. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2399 · Cited by 390
A mediator required for activation of RNA polymerase II transcription in vitro
Flanagan, P. M., Kelleher, R. J., Sayre, M. H., Tschochner, H., & Kornberg, R. D. (1991) · Nature · doi:10.1038/350436a0 · Cited by 386
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374 · cited 2×
“Specific sets of genes may be more sensitive to genetic CDK12 inhibition, resulting in decreased Ser2 phosphorylation only at some gene loci (62), whereas chemical inhibition of CDK12 and CDK13 appears to more globally dampen Ser2 phosphorylation (60).”
BackgroundBajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373 · cited 2×
“In addition, data from TCGA showed that patients with CDK12 mutations have better responses to platinum-based chemotherapy (84).”
BackgroundMethodSelf-citationCDK8 is a positive regulator of transcriptional elongation within the serum response network
Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1752 · Cited by 371
Association of Cdk-activating kinase subunits with transcription factor TFIIH
Serizawa, H., Mäkelä, T. P., Conaway, J. W., Conaway, R. C., Weinberg, R. A., & Young, R. A. (1995) · Nature · doi:10.1038/374280a0 · Cited by 367
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365 · cited 2×
“BRCA1, BRCA2, and CDK12 mutations are mutually exclusive (84–86), but despite the mounting evidence that CDK12 regulates the expression of HR genes, the genomic signature of CDK12-mutated tumors is unique from those with BRCA1 or BRCA2 mutations (87, 88).”
BackgroundHIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia
Galbraith, M. D., Allen, M. A., Bensard, C. L., Wang, X., Schwinn, M. K., Qin, B., Long, H. W., Daniels, D. L., Hahn, W. C., Dowell, R. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.048 · Cited by 359
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
TFIIH: when transcription met DNA repair
Compe, E., & Egly, J.-M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3350 · Cited by 332
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
Dubbury, S. J., Boutz, P. L., & Sharp, P. A. (2018) · Nature · doi:10.1038/s41586-018-0758-y · Cited by 318
E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8
Morris, E. J., Ji, J.-Y., Yang, F., Di Stefano, L., Herr, A., Moon, N.-S., Kwon, E.-J., Haigis, K. M., Näär, A. M., & Dyson, N. J. (2008) · Nature · doi:10.1038/nature07310 · Cited by 297
Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291
Krajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 273
Self-citationKumar, S. K., LaPlant, B., Chng, W. J., Zonder, J., Callander, N., Fonseca, R., Fruth, B., Roy, V., Erlichman, C., & Stewart, A. K. (2015) · Blood · doi:10.1182/blood-2014-05-573741 · Cited by 252
Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia
Lee, S.-H., Singh, I., Tisdale, S., Abdel-Wahab, O., Leslie, C. S., & Mayr, C. (2018) · Nature · doi:10.1038/s41586-018-0465-8 · Cited by 251
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Riaz, N., Blecua, P., Lim, R. S., Shen, R., Higginson, D. S., Weinhold, N., Norton, L., Weigelt, B., Powell, S. N., & Reis-Filho, J. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00921-w · Cited by 249
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
Sano, M., Abdellatif, M., Oh, H., Xie, M., Bagella, L., Giordano, A., Michael, L. H., DeMayo, F. J., & Schneider, M. D. (2002) · Nature Medicine · doi:10.1038/nm778 · Cited by 236
WANG, S., & FISCHER, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.003 · Cited by 232
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Self-citationWong, K. H., Jin, Y., & Struhl, K. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.024 · Cited by 225
Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA Polymerase II Transcription
Fu, T.-J., Peng, J., Lee, G., Price, D. H., & Flores, O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34527 · Cited by 223
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M., Sun, H., Morton, G., Madzo, J., Chung, W., Khowsathit, J., Perez-Leal, O., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 222
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
CDK9: a signaling hub for transcriptional control
Bacon, C. W., & D’Orso, I. (2019) · Transcription · doi:10.1080/21541264.2018.1523668 · Cited by 203
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 199
Liang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 192
The structure and substrate specificity of human Cdk12/Cyclin K
Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014) · Nature Communications · doi:10.1038/ncomms4505 · Cited by 191
Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C.
Tassan, J. P., Jaquenoud, M., Léopold, P., Schultz, S. J., & Nigg, E. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8871 · Cited by 184
Menghi, F., Barthel, F. P., Yadav, V., Tang, M., Ji, B., Tang, Z., Carter, G. W., Ruan, Y., Scully, R., Verhaak, R. G. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.008 · Cited by 174
EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173 · cited 1×
“CDK12 is critical in Ewing sarcoma, which is sensitive to CDK12 inhibitors and appears to synergize with PARPi (139).”
BackgroundCyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities
Porter, D. C., Farmaki, E., Altilia, S., Schools, G. P., West, D. K., Chen, M., Chang, B.-D., Puzyrev, A. T., Lim, C.-U., Rokow-Kittell, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206906109 · Cited by 172
Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
Lu, H., Xue, Y., Yu, G. K., Arias, C., Lin, J., Fong, S. K., Faure, M., Weisburd, B., Ji, X., Mercier, A., et al. (2015) · eLife · doi:10.7554/elife.06535 · Cited by 170
Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications
Ebmeier, C. C., Erickson, B., Allen, B. L., Allen, M. A., Kim, H., Fong, N., Jacobsen, J. R., Liang, K., Shilatifard, A., Dowell, R. D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.021 · Cited by 169
CDK11 Complexes Promote Pre-mRNA Splicing
Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210057200 · Cited by 166
Sansó, M., Levin, R. S., Lipp, J., Wang, V. Y., Greifenberg, A. K., Quezada, E. M., Ali, A., Ghosh, A., Larochelle, S., Rana, T. M., et al. (2016) · Genes & Development · doi:10.1101/gad.269589.115 · Cited by 164
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Sharifnia, T., Wawer, M. J., Chen, T., Huang, Q.-Y., Weir, B. A., Sizemore, A., Lawlor, M. A., Goodale, A., Cowley, G. S., Vazquez, F., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0312-3 · Cited by 164
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 163
Poss, Z. C., Ebmeier, C. C., Odell, A. T., Tangpeerachaikul, A., Lee, T., Pelish, H. E., Shair, M. D., Dowell, R. D., Old, W. M., & Taatjes, D. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.030 · Cited by 162
The essential and multifunctional TFIIH complex
Rimel, J. K., & Taatjes, D. J. (2018) · Protein Science · doi:10.1002/pro.3424 · Cited by 162
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Zeng, M., Kwiatkowski, N. P., Zhang, T., Nabet, B., Xu, M., Liang, Y., Quan, C., Wang, J., Hao, M., Palakurthi, S. S., et al. (2018) · eLife · doi:10.7554/elife.39030 · Cited by 162
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Olson, C. M., Liang, Y., Leggett, A., Park, W. D., Li, L., Mills, C. E., Elsarrag, S. Z., Ficarro, S. B., Zhang, T., Düster, R., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.012 · Cited by 161
Cyclin C is a haploinsufficient tumour suppressor
Li, N., Fassl, A., Chick, J., Inuzuka, H., Li, X., Mansour, M. R., Liu, L., Wang, H., King, B., Shaik, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3046 · Cited by 160
The Crystal Structure of Human CDK7 and Its Protein Recognition Properties
Lolli, G., Lowe, E. D., Brown, N. R., & Johnson, L. N. (2004) · Structure · doi:10.1016/j.str.2004.08.013 · Cited by 160
Structural and functional analysis of the Cdk13/Cyclin K complex
Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.025 · Cited by 157
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
CDK8/19 Mediator kinases potentiate induction of transcription by NFκB
Chen, M., Liang, J., Ji, H., Yang, Z., Altilia, S., Hu, B., Schronce, A., McDermott, M. S. J., Schools, G. P., Lim, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710467114 · Cited by 156
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 154
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery
Fisher, R. P. (2018) · Transcription · doi:10.1080/21541264.2018.1553483 · Cited by 154
Ekumi, K. M., Paculová, H., Lenasi, T., Pospíchalová, V., Bösken, C. A., Rybaříková, J., Bryja, V., Geyer, M., Blažek, D., & Barborič, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 153
Loss of DNA Replication Control Is a Potent Inducer of Gene Amplification
Green, B. M., Finn, K. J., & Li, J. J. (2010) · Science · doi:10.1126/science.1190966 · Cited by 149
Mechanism of tandem duplication formation in BRCA1-mutant cells
Willis, N. A., Frock, R. L., Menghi, F., Duffey, E. E., Panday, A., Camacho, V., Hasty, P., Liu, E. T., Alt, F. W., & Scully, R. (2017) · Nature · doi:10.1038/nature24477 · Cited by 147
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis
Wyllie, S., Thomas, M. G., Patterson, S., Crouch, S., Rycker, M. D., Lowe, R., Gresham, S., Urbaniak, M. D., Otto, T. D., Stojanovski, L., et al. (2018) · Nature · doi:10.1038/s41586-018-0356-z · Cited by 146
Chen, H.-H., Wang, Y.-C., & Fann, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2736-2745.2006 · Cited by 144
Cyclin K goes with Cdk12 and Cdk13
Kohoutek, J., & Blažek, D. (2012) · Cell Division · doi:10.1186/1747-1028-7-12 · Cited by 142
Regulatory functions of the Mediator kinases CDK8 and CDK19
Fant, C. B., & Taatjes, D. J. (2018) · Transcription · doi:10.1080/21541264.2018.1556915 · Cited by 141
McDermott, M. S. J., Chumanevich, A. A., Lim, C., Liang, J., Chen, M., Altilia, S., Oliver, D., Rae, J. M., Shtutman, M. S., Kiaris, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14894 · Cited by 139
Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors
Loyer, P., Trembley, J. H., Grenet, J. A., Busson, A., Corlu, A., Zhao, W., Koçak, M., Kidd, V. J., & Lahti, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708188200 · Cited by 133
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Effron, S. S., Mitchell-Velasquez, E., Posimo, J. M., Carskadon, S. L., Baca, S. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0189 · Cited by 133
Ko, T. K., Kelly, E., & Pines, J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.14.2591 · Cited by 132
Popova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1‐ErbB‐PI3K signaling
Choi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H.-Y., Park, M. K., Son, T., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948058 · Cited by 129
Cdk12 is essential for embryonic development and the maintenance of genomic stability
Juan, H. U., Lin, Y.-J., Chen, H.-R., & Fann, M.-J. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.157 · Cited by 126
Cheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
Herrmann, C. H., & Mancini, M. A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.8.1491 · Cited by 124
The tandem duplicator phenotype as a distinct genomic configuration in cancer
Menghi, F., Inaki, K., Woo, X., Kumar, P., Grzȩda, K. R., Malhotra, A., Yadav, V. K., Kim, H., Márquez, E. J., Ucar, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520010113 · Cited by 124
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
Manavalan, A. P. C., Pilařová, K., Kluge, M., Bartholomeeusen, K., Rájecký, M., Oppelt, J., Khirsariya, P., Paruch, K., Krejčí, L., Friedel, C. C., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847592 · Cited by 122
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 118
Self-citationCyclin‐dependent kinase 9–cyclin K functions in the replication stress response
Yu, D. S., Zhao, R., Hsu, E., Cayer, J., Ye, F., Guo, Y. P., Shyr, Y., & Cortez, D. (2010) · EMBO Reports · doi:10.1038/embor.2010.153 · Cited by 116
CDK8 Kinase Activity Promotes Glycolysis
Galbraith, M. D., Andrysík, Z., Pandey, A., Hoh, M., Bonner, E. A., Hill, A. A., Sullivan, K. D., & Espinosa, J. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.058 · Cited by 111
Therapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
Natrajan, R., Wilkerson, P. M., Marchiò, C., Piscuoglio, S., Ng, C. K. Y., Wai, P. T., Lambros, M. B. K., Samartzis, E. P., Dedes, K. J., Frankum, J. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4325 · Cited by 110
Self-citationFirestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E. F., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., & Ogino, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24908 · Cited by 109
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
McBride, D. J., Etemadmoghadam, D., Cooke, S. L., Alsop, K., George, J., Butler, A. P., Cho, J., Galappaththige, D., Greenman, C., Howarth, K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4042 · Cited by 102
Clarke, P. A., Ortiz-Ruiz, M.-J., Poele, R. T., Adeniji-Popoola, O., Box, G., Court, W., Czasch, S., Bawab, S. E., Esdar, C., Ewan, K., et al. (2016) · eLife · doi:10.7554/elife.20722 · Cited by 102
Lin, T. S., Blum, K. A., Fischer, D. B., Mitchell, S. M., Ruppert, A. S., Porcu, P., Kraut, E. H., Baiocchi, R. A., Moran, M. E., Johnson, A. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1570 · Cited by 99
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability
Choi, S. H., Martinez, T. F., Kim, S., Donaldson, C. J., Shokhirev, M. N., Saghatelian, A., & Jones, K. A. (2019) · Genes & Development · doi:10.1101/gad.322339.118 · Cited by 95
A Role for the TFIIH XPB DNA Helicase in Promoter Escape by RNA Polymerase II
Moreland, R. J., Tirode, F., Yan, Q., Conaway, J. W., Egly, J., & Conaway, R. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22127 · Cited by 93
The emerging roles of CDK12 in tumorigenesis
Paculová, H., & Kohoutek, J. (2017) · Cell Division · doi:10.1186/s13008-017-0033-x · Cited by 93
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells
Koehler, M. F. T., Bergeron, P., Blackwood, E. M., Bowman, K. K., Clark, K., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00278 · Cited by 90
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome
Guen, V. J., Gamble, C., Flajolet, M., Unger, S., Thollet, A., Ferandin, Y., Superti‐Furga, A., Cohen, P. A., Meijer, L., & Colas, P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306814110 · Cited by 89
Rosonina, E., & Blencowe, B. J. (2004) · RNA · doi:10.1261/rna.5207204 · Cited by 88
A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response
Audetat, K. A., Galbraith, M. D., Odell, A. T., Lee, T., Pandey, A., Espinosa, J. M., Dowell, R. D., & Taatjes, D. J. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00626-16 · Cited by 86
Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation
Lei, T., Zhang, P., Zhang, X., Xiao, X., Zhang, J., Qiu, T., Dai, Q., Zhang, Y., Min, L., Li, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04258-w · Cited by 81
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors
Gao, Y., Zhang, T., Terai, H., Ficarro, S. B., Kwiatkowski, N. P., Hao, M.-F., Sharma, B., Christensen, C. L., Chipumuro, E., Wong, K., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.11.007 · Cited by 80
Pawar, A., Gollavilli, P. N., Wang, S., & Asangani, I. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.011 · Cited by 79
Zhou, Y., Han, C., Li, D., Yu, Z., Li, F., Li, F., An, Q., Bai, H., Zhang, X., Duan, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep10433 · Cited by 78
Thomas, D., Powell, J. A., Vergez, F., Segal, D., Nguyen, N.-Y. N., Baker, A., Teh, T., Barry, E. F., Sarry, J., Lee, E. M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447441 · Cited by 74
Ito, M., Tanaka, T., Toita, A., Uchiyama, N., Kokubo, H., Morishita, N., Klein, M. G., Zou, H., Murakami, M., Kondo, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00683 · Cited by 73
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Cyclin-Dependent Kinase 12 Increases 3′ End Processing of Growth Factor-Induced c-FOS Transcripts
Eifler, T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jäger, S., Johnson, J. R., Luo, Z., Krogan, N. J., & Peterlin, B. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01157-14 · Cited by 70
RBPJ maintains brain tumor–initiating cells through CDK9-mediated transcriptional elongation
Xie, Q., Wu, Q., Kim, L. J. Y., Miller, T. E., Liau, B. B., Mack, S. C., Yang, K., Factor, D. C., Fang, X., Huang, Z., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86114 · Cited by 67
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
Bergeron, P., Koehler, M. F. T., Blackwood, E. M., Bowman, K. K., Clark, K., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00044 · Cited by 65
Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
Antonarakis, E. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmcibr1808772 · Cited by 65
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
Ng, C. K. Y., Cooke, S. L., Howe, K., Newman, S., Xian, J., Temple, J., Batty, E. M., Pole, J. C. M., Langdon, S. P., Edwards, P. A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3980 · Cited by 63
Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, J. W., Denz, C. R., Su, N., Wu, A. J., Impastato, A. C., Mlynarski, S. N., Varnes, J. G., Prince, D. B., Cidado, J. R., Gao, N., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700695 · Cited by 62
Brägelmann, J., Dammert, M. A., Dietlein, F., Heuckmann, J. M., Choidas, A., Böhm, S., Richters, A., Basu, D., Tischler, V., Lorenz, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.082 · Cited by 60
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
Jia, B., Choy, E., Cote, G. M., Harmon, D. C., Ye, S., Kan, Q., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.040 · Cited by 57
Cdk11-CyclinL Controls the Assembly of the RNA Polymerase II Mediator Complex
Drogat, J., Migeot, V., Mommaerts, E., Mullier, C., Dieu, M., van Bakel, H., & Hermand, D. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.027 · Cited by 56
Abida, W. M., Bryce, A. H., Vogelzang, N. J., Amato, R. J., Percent, I. J., Shapiro, J., McDermott, R., Hussain, A., Patnaik, A., Petrylak, D. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy284.002 · Cited by 54
RNA polymerase II structure, and organization of the preinitiation complex
Asturias, F. J. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.03.007 · Cited by 52
Spangler, L., Wang, X., Conaway, J. W., Conaway, R., & Dvir, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101004498 · Cited by 48
Chen, H., Lin, G.-T., Huang, C.-K., & Fann, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.024 · Cited by 47
Li, X., Chatterjee, N., Spirohn, K., Boutros, M., & Bohmann, D. (2016) · Scientific Reports · doi:10.1038/srep21455 · Cited by 47
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
Henry, K. L., Kellner, D., Bajrami, B., Anderson, J. E., Beyna, M., Bhisetti, G., Cameron, T. O., Capacci, A. G., Bertolotti‐Ciarlet, A., Feng, J., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aam8216 · Cited by 40
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
Paculová, H., Kramara, J., Šimečková, Š., Fedr, R., Souček, K., Hylse, O., Paruch, K., Svoboda, M., Mistrík, M., & Kohoutek, J. (2017) · Tumor Biology · doi:10.1177/1010428317727479 · Cited by 36
Heterochromatin remodeling by CDK12 contributes to learning in Drosophila
Pan, L., Xie, W., Li, K.-L., Yang, Z., Jiang, X., Zhang, W., Liu, L., Ren, X., He, Z., Wu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502943112 · Cited by 23
CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment
Even, Y., Escande, M., Fayet, C., & Genevière, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149184 · Cited by 23
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics
Nojima, T., & Proudfoot, N. J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00447-6 · Cited by 420
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Metadata
- Authors
- Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A.
- Venue
- Cancer Discovery
- Published
- 2020-03-01
- Volume
- 10
- Issue
- 3
- Pages
- 351-370
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3007726005
- Cited by
- 287
- References
- 157
- FWCI
- 19.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.